Skip to main content
SpringerLink
Log in

Donepezil: a step forward compared with tacrine for Alzheimer’s disease?

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Selkoe DJ. Aging brain, aging mind. Sei Am 1992; 267: 135–42

    Google Scholar 

  2. Bryson HM, Benfield P. Donepezil. Drugs Aging 1997 Mar; 10(3): 234–9

    Article  PubMed  CAS  Google Scholar 

  3. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer’s disease. Drugs Aging 1994 Jun; 4: 510–40

    Article  PubMed  CAS  Google Scholar 

  4. Gillis JC, Benfield P, McTavish D. Idebenone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging 1994 Aug; 5: 133–52

    Article  PubMed  CAS  Google Scholar 

  5. Rho JP, Lipson LG. Focus on donepezil. Formulary 1997 Jul; 32(7): 677–84

    CAS  Google Scholar 

  6. Watkins PB, Zimmerman HJ, Knapp MJ. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994 Apr 6; 271: 992–8

    Article  PubMed  CAS  Google Scholar 

  7. Aniracetam: preliminary evidence of efficacy warrants further comparative studies. Drug Ther Perspect 1994 Oct 3; 4 (7): 4–7

  8. Tacrine offers modest benefits in some patients with Alzheimer’s disease. Drug Ther Perspect 1994 Dec 12; 4 (12): 1–4

  9. Rogers SL, Walters EJ, Friedhoff LT. The pharmacokinetics (PK) and pharmacodynamics(PD) of E2020, ((R,S,)-1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)-methylpiperidine hydrochloride), a novel inhibitor of acetylcholinesterase (AChE): implications for use in the treatment of Alzheimer’s disease [abstract]. Neurobiol Aging 1992; 13(1): 496

    Google Scholar 

  10. Rogers SL, Friedhoff LT, Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293–303

    PubMed  CAS  Google Scholar 

  11. Mihara M, Ohnishi A, Tomono Y, et al. Pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 1993 May; 31: 223–9

    PubMed  CAS  Google Scholar 

  12. Rogers SL, Doody R, Mohs R. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer’s disease: results of a 30-week phase III trial [abstract]. Neurology 1996 Feb; 46 Suppl.: A217

    Google Scholar 

  13. Rogers SL, Perdomo C, Friedhoff LT. Clinical benefits are maintained during long-term treatment of Alzheimer’s disease with the acetylcholinesterase inhibitor, E2020 [abstract no. P-8-21]. Eur Neuropsychopharmacol 1995; 5(3): 386–7

    Article  Google Scholar 

  14. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994 Mar; 151: 390–6

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Donepezil: a step forward compared with tacrine for Alzheimer’s disease?. Drugs Ther. Perspect 11, 6–8 (1998). https://doi.org/10.2165/00042310-199811030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199811030-00002

Search

Navigation